Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

-0.18 (-0.86%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
367,583 shs
Average Volume
1.14 million shs
Market Capitalization
$1.77 billion
P/E Ratio
Dividend Yield
Price Target

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
65.5% Upside
$34.42 Price Target
Short Interest
11.32% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
-0.05mentions of Syndax Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.70) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.04 out of 5 stars

Medical Sector

367th out of 909 stocks

Pharmaceutical Preparations Industry

160th out of 423 stocks

SNDX stock logo

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

SNDX Stock News Headlines

He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
SNDX Apr 2024 17.500 put
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$139.71 million
Book Value
$6.53 per share


Free Float
Market Cap
$1.77 billion
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Michael A. Metzger M.B.A.Mr. Michael A. Metzger M.B.A. (Age 53)
    CEO & Director
    Comp: $1.1M
  • Dr. Peter Ordentlich B.Sc. (Age 55)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Dr. Richard A. Heyman Ph.D. (Age 67)
  • Dr. Ronald M. Evans Ph.D. (Age 75)
    Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D.
  • Sharon Klahre
    Vice President of Investor Relations & Communications
  • Mr. Kevin McManus (Age 55)
    Chief People Officer
  • Dr. Joseph Paul Eder M.D.
    Member of Scientific Advisory Board & Chief Medical Officer
  • Dr. Anjali Ganguli Ph.D. (Age 47)
    Chief Business Officer
    Comp: $450.58k
  • Mr. Steven Closter
    Chief Commercial Officer

SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price target for 2024?

10 brokerages have issued 12-month target prices for Syndax Pharmaceuticals' stock. Their SNDX share price targets range from $23.00 to $45.00. On average, they expect the company's stock price to reach $34.42 in the next twelve months. This suggests a possible upside of 65.5% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2024?

Syndax Pharmaceuticals' stock was trading at $21.61 on January 1st, 2024. Since then, SNDX shares have decreased by 3.8% and is now trading at $20.79.
View the best growth stocks for 2024 here

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SNDX earnings forecast

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its earnings results on Tuesday, February, 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.01. During the same quarter last year, the business earned ($0.62) earnings per share.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.33%), Diversified Trust Co (0.02%) and Mesirow Financial Investment Management Inc. (0.01%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury.
View institutional ownership trends

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 4/24/2024 by Staff

From Our Partners